Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

67 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Routine clinical use of alemtuzumab in patients with heavily pretreated B-cell chronic lymphocytic leukemia: a nation-wide retrospective study in Austria.
Fiegl M, Falkner A, Hopfinger G, Brugger S, Zabernigg A, Bauer F, Haslbauer F, Demirtas D, Grossschmidt P, Tatzreiter G, Gastl G, Greil R; Austrian Collaborative Study Group on Alemtuzumab in Chronic Lymphocytic Leukemia. Fiegl M, et al. Among authors: hopfinger g. Cancer. 2006 Nov 15;107(10):2408-16. doi: 10.1002/cncr.22263. Cancer. 2006. PMID: 17054106 Free article.
Clinical outcome of pretreated B-cell chronic lymphocytic leukemia following alemtuzumab therapy: a retrospective study on various cytogenetic risk categories.
Fiegl M, Erdel M, Tinhofer I, Brychtova Y, Panovska A, Doubek M, Eigenberger K, Fonatsch C, Hopfinger G, Mühlberger H, Zabernigg A, Falkner F, Gastl G, Mayer J, Greil R; Austrian Collaborative Study Group on Alemtuzumab in Chronic Lymphocytic Leukemia, in cooperation with The Czech Leukemia Study Group for Life, CELL. Fiegl M, et al. Among authors: hopfinger g. Ann Oncol. 2010 Dec;21(12):2410-2419. doi: 10.1093/annonc/mdq236. Epub 2010 May 13. Ann Oncol. 2010. PMID: 20466745 Free article.
Successful alemtuzumab retreatment in progressive B-cell chronic lymphocytic leukemia: a multicenter survey in 30 patients.
Fiegl M, Falkner F, Steurer M, Zojer N, Hopfinger G, Haslbauer F, Winder G, Voskova D, Andel J, Lang A, Brychtova Y, Mayer J, Greil R, Gastl G; Austrian Collaborative Study Group on Alemtuzumab in Chronic Lymphocytic Leukemia; Czech Leukemia Study Group for Life; CELL. Fiegl M, et al. Among authors: hopfinger g. Ann Hematol. 2011 Sep;90(9):1083-91. doi: 10.1007/s00277-011-1192-5. Epub 2011 Feb 25. Ann Hematol. 2011. PMID: 21350830
Novel treatment avenues for peripheral T-cell lymphomas.
Hopfinger G, Griessl R, Sifft E, Taylor N, Kenner L, Greil R, Merkel O. Hopfinger G, et al. Expert Opin Drug Discov. 2012 Dec;7(12):1149-63. doi: 10.1517/17460441.2012.727392. Epub 2012 Sep 24. Expert Opin Drug Discov. 2012. PMID: 22998641 Review.
[71-year old woman with neutropenic fever during chemotherapy].
Schlick K, Datz L, Hohla F, Greil R, Hopfinger G. Schlick K, et al. Among authors: hopfinger g. Dtsch Med Wochenschr. 2013 Oct;138(41):2091-2. doi: 10.1055/s-0033-1349528. Epub 2013 Oct 1. Dtsch Med Wochenschr. 2013. PMID: 24085362 German. No abstract available.
Alemtuzumab in chronic lymphocytic leukemia: final results of a large observational multicenter study in mostly pretreated patients.
Fiegl M, Stauder R, Steurer M, Mian M, Hopfinger G, Brychtova Y, Skrabs C, Zabernigg A, Schmid F, Haslbaur F, Winder G, Walder A, Lang A, Voskova D, Greil R, Mayer J, Gastl G; Austrian Collaborative Study Group on Alemtuzumab in Chronic Lymphocytic Leukemia, in cooperation with The Czech Leukemia Study Group for Life, CELL. Fiegl M, et al. Among authors: hopfinger g. Ann Hematol. 2014 Feb;93(2):267-77. doi: 10.1007/s00277-013-1966-z. Epub 2013 Nov 30. Ann Hematol. 2014. PMID: 24292560 Clinical Trial.
67 results